ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 400 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $59.54, for a total transaction of $23,816.00. Following the completion of the sale, the vice president now owns 83,478 shares in the company, valued at $4,970,280.12. This represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $53.92, for a total transaction of $21,568.00.

ANI Pharmaceuticals Stock Down 0.2 %

ANIP stock opened at $58.82 on Wednesday. The firm’s fifty day simple moving average is $56.98 and its 200-day simple moving average is $58.23. The company has a market capitalization of $1.24 billion, a P/E ratio of -106.94 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81.

Analysts Set New Price Targets

Several analysts have weighed in on ANIP shares. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price on the stock. Finally, Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $77.71.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently made changes to their positions in ANIP. US Bancorp DE lifted its stake in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares during the period. KBC Group NV lifted its stake in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 600 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $166,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the period. Finally, Rafferty Asset Management LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $200,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.